Clinical Trials Browser

Withdrawn × INDUSTRY × atezolizumab × Clear all

NCT06719973 2025-06-17

Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

Phase 1 Withdrawn

Other solid neoplasm

Advanced Solid Tumors

NCT06331598 2024-12-24

IMperator

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumors

NCT03973333 2024-10-18

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Phase 1/2 Withdrawn

Other solid neoplasm

Select Advanced Solid Tumors

NCT06099418 2024-09-20

Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Phase 2 Withdrawn

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

NCT06090318 2023-10-19

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Phase 1/2 Withdrawn

DermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Mesothelioma, Stomach Neoplasms

NCT04611776 2021-06-16

CATHAYA

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT04267237 2021-02-04

A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT03693573 2018-11-15

A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma

Phase 3 Withdrawn

Carcinoma, Renal Cell

NCT03369964 2018-04-05

A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1 Withdrawn

Lymphoma, Non-Hodgkin